Jun 8, 2025, 10:02
Reviewing the Highlights of ASCO 2025 – Tres Uramigas
Tres Uramigas shared a post on X:
“Reviewing the highlights of ASCO25
AMPLITUDE marks a before and after in CPHSm HRR+. Niraparib + Abiraterone improves:
rPFS (HR 0.63)
Time to symptomatic progression (HR 0.50)
Trend in SG (HR 0.79)
Possible new standard in 1L?
In the BRCA1/2 subgroup:
rPFS (HR 0.52)
Time to symptomatic progression (HR 0.44)
SG (HR 0.75)
Most common G3-4 AEs: anemia (29 %) and hypertension (26 %). Low discontinuation rates due to toxicity (11 %).
You can listen to Gert Attard analyzing this data from ASCO 2025 along with Tom Powles and Brian Rini below.”
More posts featuring Tres Uramigas.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53
Jun 8, 2025, 09:53
Jun 8, 2025, 09:31
Jun 8, 2025, 09:15